Sugi Predict

Sugi Predict / Compounds / SCHEMBL141545

SCHEMBL141545

SCHEMBL141545

Cc1cc(C)c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc32)[nH]1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RET P07949 11/20 0.61
▸ PDGFRB P09619 4/20 0.57
▸ KDR P35968 5/20 0.55
▸ FLT3 P36888 5/20 0.55
▸ ALK Q9UM73 5/20 0.55
▸ CSF1R P07333 3/20 0.55
▸ FGFR1 P11362 3/20 0.55
▸ SRC P12931 3/20 0.55
▸ FGFR3 P22607 3/20 0.55
▸ FLT4 P35916 3/20 0.55
▸ ABL1 P00519 3/20 0.55
▸ NTRK1 P04629 3/20 0.55
▸ FLT1 P17948 2/20 0.55
▸ MAPK1 P28482 2/20 0.55
▸ PDPK1 O15530 2/20 0.55
▸ MEN1 O00255 2/20 0.55
▸ KIT P10721 2/20 0.55
▸ PDGFRA P16234 2/20 0.55
▸ FGFR2 P21802 2/20 0.55
▸ BLM P54132 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL147703 0.88 KDR (0.55) RETPDGFRBKDRFLT3ALK
SCHEMBL141995 0.85 RET (0.61) RETPDGFRBKDRFLT3ALK
SCHEMBL144252 0.82 KDR (0.68) RETPDGFRBKDRFLT3ALK
SCHEMBL144683 0.82 SRC (0.56) RETPDGFRBKDRFLT3ALK
SCHEMBL144169 0.81 SRC (0.55) RETPDGFRBKDRFLT3ALK
SCHEMBL145476 0.81 MET (0.67) RETPDGFRBKDRFLT3ALK
SCHEMBL144892 0.81 KDR (0.61) RETPDGFRBKDRFLT3ALK
SCHEMBL142485 0.81 SRC (0.60) RETPDGFRBKDRFLT3ALK
SCHEMBL142682 0.81 SRC (0.55) RETPDGFRBKDRFLT3ALK
SCHEMBL144378 0.81 KDR (0.66) RETPDGFRBKDRFLT3ALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 — — US claimed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 — — US claimed
US-20140221455-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR Verva Pharmaceuticals, Inc. (AU) 2014-08-07 — — US disclosed
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR VERVA PHARMACEUTICALS PTY LTD (AU) 2012-03-08 — — US disclosed
US-20050282733-A1 Differentiation modulating agents and uses therefor VERVA PHARMACEUTICALS PTY LTD (AU) 2005-12-22 — — US disclosed
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 — — US disclosed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR FGF1, FABP4, FGF2 RET 2074/4885PDGFRB 467/4885KDR 1077/4885
US-20050282733-A1 Differentiation modulating agents and uses therefor FGF1, FABP4, FGF2 RET 2074/4885PDGFRB 467/4885KDR 1077/4885
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS DMPK, ADK, MAP3K20 RET 246/4885PDGFRB 348/4885KDR 398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.